OCT 19·SEC EDGARLow
Rajasekar Sunil purchased $12K of HQY
Rajasekar Sunil (EVP Chief Prod & Strat Officer) purchased 131 shares of HEALTHEQUITY, INC. (HQY) at an average of $91.16 ($90.33–$95.06) across 2 trades over 2026-07-08 to 2026-10-15.
StockNASDAQ · US · USDHealthcare · Health Information Services
$HQY
HEALTHEQUITY, INC.
AlphAI earnings readSecond quarter of fiscal 2027 · AUG 27HealthEquity reported second-quarter revenue of $350.7 million, up 8%, with net income up 10% to $65.6 million and Adjusted EBITDA up 11% to $167.0 million; management raised fiscal 2027 guidance.Verdict: strongRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $HQYvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $HQY in the last 7 days.
Insider · 30dAll trades →
- Buys
- $10K 1 txs
- Sells
- — 0 txs
Rajasekar Sunil1× · $10K
10b5-1 share of filings0%
Top stories · $HQYMore →
OCT 13·investing.com
Jefferies examines HealthEquity stock short interest rise
Jefferies reported that short interest in HealthEquity (HQY) rose to 7.2% of diluted shares as of September 30. The firm cited concerns over treasury rate exposure, marketplace adoption, and declining HSA cash balances. Short interest in healthcare services and IT stocks increased 0.1% for the two-week period ended September 30.
OCT 9·tradingview.com
HealthEquity terminates Chief Commercial Officer Michael Fiore, CCO duties redistributed
HealthEquity terminated Chief Commercial Officer Michael Fiore, effective October 5, 2026. His responsibilities will be redistributed among other management team members. The company did not disclose the reason for his termination. According to the SEC filing, no changes were made to the board or committee roles.
HQY sentiment & insider activity
Recent HQY coverage spans financial news, earnings and insider activity.
In the last 30 days, HQY insiders filed 1 SEC Form 4 transaction — 1 purchase ($10K) and no sales. The most active reporter was Rajasekar Sunil, EVP Chief Prod & Strat Officer, with 1 filing.
What's driving HQY
Minor insider purchase suggests modest confidence but size is too small to move price.
Higher short interest and the cited HSA cash-balance and rate-lock dynamics may keep downside pressure or raise borrow/positioning risk.
Leadership change in commercial function could signal internal restructuring or performance concerns, but the filing provides no reason or replacement details.
C-suite churn at the commercial leadership level, with severance and equity handling disclosed, may shift near-term execution risk and internal ownership of revenue initiatives.
HQY could attract health‑sector growth investors.
AlphAI scores every news story that mentions HQY with an AI model for sentiment and relevance, and aggregates insider trades from HEALTHEQUITY, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $HQY
Score
Rajasekar Sunil purchased $12K of HQY
Rajasekar Sunil (EVP Chief Prod & Strat Officer) purchased 131 shares of HEALTHEQUITY, INC. (HQY) at an average of $91.16 ($90.33–$95.06) across 2 trades over 2026-07-08 to 2026-10-15.
1 min readJefferies examines HealthEquity stock short interest rise
Jefferies reported that short interest in HealthEquity (HQY) rose to 7.2% of diluted shares as of September 30. The firm cited concerns over treasury rate exposure, marketplace adoption, and declining HSA cash balances. Short interest in healthcare services and IT stocks increased 0.1% for the two-week period ended September 30.
4 min read
HealthEquity terminates Chief Commercial Officer Michael Fiore, CCO duties redistributed
HealthEquity terminated Chief Commercial Officer Michael Fiore, effective October 5, 2026. His responsibilities will be redistributed among other management team members. The company did not disclose the reason for his termination. According to the SEC filing, no changes were made to the board or committee roles.
1 min readHEALTHEQUITY, INC. (HQY): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
HEALTHEQUITY, INC. (HQY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02(b) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The employment of Michael Fiore, the Chief Commercial Officer at HealthEquity, Inc. (the “Company”), was terminated by t
2 min readUBS flags 56 stocks where growth and profitability may be underpriced
UBS identified 56 U.S. stocks with strong growth, profitability, and improving earnings, arguing their valuations may not fully reflect fundamentals. The basket includes NVIDIA, Broadcom, Microsoft, and others, with a 15% forward sales CAGR, twice the S&P 500's rate, and a 34% median HOLT CFROI.
2 min readHealthEquity Appoints Moody’s CFO Noémie Heuland to Board of Directors
HealthEquity, Inc. (HQY) added Noémie Heuland, CFO of Moody’s (MCO), to its board of directors. Heuland will also serve on the Audit and Risk and Cybersecurity and Technology committees. She brings finance and technology experience to the company, which manages nearly 18 million health savings accounts.
1 min readS&P Global upgrades HealthEquity rating on strong performance
S&P Global Ratings upgraded HealthEquity (HQY) to 'BB+' from 'BB', citing growth and higher interest rates. The firm expects 8% revenue growth in fiscal 2027 and adjusted margins to rise to 41.5%. HealthEquity benefits from increasing HSA relevance and plans to use excess cash for share repurchases. S&P anticipates leverage to drop to 1.2x by 2027.
2 min readHealthEquity (HQY) Raises Guidance As Earnings Put Valuation Back In Focus
HealthEquity (HQY) reported higher Q2 revenue and net income, raising full-year earnings guidance. Despite this, shares are down 8% over the past month, contrasting with a 5% 1-year and 41% 3-year total return. The stock's valuation is now under scrutiny, with a fair value estimate of $115.56, but it trades at a higher P/E ratio compared to industry peers.
2 min read
HealthEquity (HQY) Q2 2027 Earnings Call Transcript
HealthEquity (HQY) reported Q2 2027 revenue of $350.7M, up 8% YoY, and adjusted EBITDA of $167M, up 11%. HSA assets grew 14% to $37.9B. The company raised full-year revenue guidance to $1.411B-$1.421B and adjusted EBITDA to $628M-$636M. Management highlighted growth in custodial and service revenue, as well as operational efficiencies from AI and technology investments.
3 min read
HealthEquity: Adjusted EBITDA Margin Hits Record 48% As HSA Assets Grow 14% To $37.9 Billion
HealthEquity reported Q2 revenue of $350.7M, up 8% YoY. Adjusted EBITDA rose 11% to $167M, with a record margin of 48%. HSA assets grew 14% to $37.9B. Net income increased 10% to $65.6M. The company raised fiscal 2027 guidance, citing strong execution and operating leverage.
2 min read